



SCRIP AWARDS — 2024 —

WEDNESDAY 4 DECEMBER 2024 · RAFFLES LONDON AT THE OWO

ENTRY GUIDE

ENTRY
DEADLINE:
12 JULY 2024



www.citeline.com/awards/ScripAwards

ENTRY AND GENERAL ENQUIRIES:

Jo Kirkpatrick, Senior Events Manager

Tel: +44 (0) 7917 555 986 · Email: Jo.Kirkpatrick@citeline.com

ENTRY
DEADLINE:
12 JULY 2024

WHY ENTER?

Entering its 20th year, the Scrip Awards unites over 400 industry leaders, commemorating and honoring the innovations and accomplishments in the global biopharma landscape.

Winners will be celebrated across 14 categories, covering a full spectrum of industry advances, from Best New Drug, Community Partnership of the Year, Best Contract Research Organization and Best Oncology R&D Advance.

All entries will be carefully reviewed by an independent Judging Panel - a group of senior industry experts from around the world, handpicked for their experience and objectivity.

This prestigious annual event of networking and celebration will incorporate a gala black-tie dinner and Awards ceremony, on Wednesday, 4 December at the newly restored OWO in London.

- ◇ Gain industry recognition by showcasing your company's outstanding achievements.
- ◇ Be celebrated as a specialist within your field of biopharma, and a key contributor to the global healthcare market.
- ◇ Acquire a competitive edge and drive business growth by being in the running for one of the industry's highest accolades.
- ◇ These awards are not just for big businesses, they very much champion small businesses too - winners will be those with the smartest innovations.

The Scrip Awards are free to enter. The closing date for entries is 12 July 2024, and the qualifying period for submissions is 1 July 2023 - 30 June 2024. Judging will take place throughout the summer, and the shortlist will be announced in September 2024.

“A great evening with our Industry's finest, celebrating incredible achievements!”

Parexel

CATEGORIES

1. Community Partnership of the Year
2. MSD's Innovation Award
3. Clinical Advance of the Year
4. Licensing Deal of the Year
5. Quris-AI Best Partnership Alliance Award
6. Business Development Team of the Year
7. Executive of the Year
8. Best Contract Research Organization - Full-Service Providers
9. Best Contract Research Organization - Specialist Providers
10. Biotech Company of the Year
11. Best New Drug Award
12. Best Oncology R&D Advance
13. Pharma Company of the Year
14. Scrip's Lifetime Achievement Award

www.citeline.com/awards/ScripAwards

ENTRY AND GENERAL ENQUIRIES:
Jo Kirkpatrick, Senior Events Manager
Tel: +44 (0) 7917 555 986 • Email: jo.kirkpatrick@citeline.com

WHO CAN ENTER?

The Scrip Awards are open to any research-based pharmaceutical or biotech company operating anywhere around the world, including third-party and partner companies supplying services to the pharmaceutical industry. Entries are free of charge.

ENTRY DEADLINE:
12 JULY 2024



HOW TO ENTER



VISIT www.citeline.com/awards/scripawards



SELECT your category or categories



CREATE your online account



COMPLETE your online entry form(s) explaining why you or your company should be considered a winner this year. Please refer to the category criteria as a guide.



SUBMIT your entry and you will receive an automated submission receipt

www.citeline.com/awards/ScripAwards

ENTRY AND GENERAL ENQUIRIES:

Jo Kirkpatrick, Senior Events Manager

Tel: +44 (0) 7917 555 986 • Email: jo.kirkpatrick@citeline.com

COMMUNITY PARTNERSHIP OF THE YEAR

This Award is designed to acknowledge the numerous ways in which pharma and biotech companies give back to the wider community. This could include outreach within a local community, with a charity or patient advocacy group, or alongside an NGO or humanitarian organization.

The judges will be looking for effective partnership activity, which took place between 1 July 2023 - 30 June 2024, to the benefit of humankind.

For example, these types of partnerships could include patient and carer support programs, educational programs or disease awareness campaigns or even a social media campaign that went viral.

To enter this category, please answer the following:

- ◆ Please give the name of the entering company and the name of the partnership
- ◆ Please outline the nature of the partnership being entered
- ◆ What were the aims of the partnership?
- ◆ What were the benefits of the partnership and how were they measured?
- ◆ What lessons were learned from the partnership and how might it be improved in future?

MSD'S INNOVATION AWARD



This category will acknowledge and celebrate outstanding scientific or technological breakthroughs which the judging panel believes have the potential to transform in the discovery or development of new medicines.

The Award is open to any person, group or company that has achieved a genuinely ground-breaking advance during the qualifying period of 1 July 2023 - 30 June 2024.

We welcome entries from parties that are active in the life sciences ecosystem - from early-stage research through to clinical proof-of-concept developments.

Achievements we wish to recognise include: insights that advance our understanding of disease biology; new therapeutic targets or approaches; elucidation of a novel mechanism of action; clinical proof of concept of a novel mechanism or novel target; and techniques and technology platforms that enhance the medical benefits of new or existing medicines.

Entries will be judged on the answers to a number of key questions:

- ◆ What is the scientific, technological or medical challenge they are targeting?
- ◆ What is the solution to the challenge?
- ◆ What proof of principle or concept has been achieved?
- ◆ How will the entry impact either the discovery or development of innovative therapeutic approaches?
- ◆ How novel is the innovation?

CLINICAL ADVANCE OF THE YEAR

This Award seeks to recognise success in a clinical trial of a new drug product (biological or chemical) that is expected to lead to an advance in healthcare.

This might include the first demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a potential new or expanded indication for an already marketed product. The product involved need not yet be approved, but the judges will be looking for innovation, clear proof of benefit and potential commercial reward.

To be eligible, the study in question must have been presented for peer review at a major medical meeting or been published in a scientific journal between 1 July 2023 - 30 June 2024.

Entrants must have played a role in the clinical study, and all joint parties must be disclosed in the application.



To enter this category, please answer the following:

- ◇ Please give full details of the study, ie, its name (protocol ID, trial identifier), phase, disease type and patients segment studied, sponsors, and the primary drug tested.
- ◇ Please summarize the major findings of the study, including all primary/co-primary and main secondary endpoints, and safety endpoints.
- ◇ How does the drug work in the setting tested?
- ◇ How do these findings represent a potential leap forward in therapy, or fulfil an unmet medical need?
- ◇ What could be the potential market size of this breakthrough?

LICENSING DEAL OF THE YEAR

Licensing is vital both in helping to keep pharma's pipelines replenished and in generating income for smaller firms.

Deals considered here are those that involve the licensing of a particular drug, project or group of closely related drugs/projects from one company to another for further development and/or marketing. Please note, it does not include more involved partnerships between companies to explore particular therapeutic strategies (see Criteria for the Best Partnership Alliance).

In choosing the winner of Scrip's Licensing Deal of the Year Award, the judges will look at all aspects of the submitted transactions, from their monetary and strategic value, to the benefits they give to both sides. To qualify, licensing deals must have been closed between 1 July 2023 - 30 June 2024.

To enter this category, please answer the following:

- ◇ Please outline the structure of the deal, giving the names of the parties involved, the drug candidate(s) concerned, and what rights it covers.
- ◇ What is the monetary value of the deal in up-front and milestone payments?
- ◇ What is the geographic spread of the deal? Does it allow any party to enter new markets?
- ◇ What is the strategic value of the licensed product to the licensee's business?
- ◇ Please explain how the licensed product was the best possible candidate to complement the rest of the licensee's pipeline or particular disease franchise.

Important note:

Would your entry fit better in the Best Partnership Alliance category? Please consider before you enter. View our Licensing Deal of the Year example entry form [here](#)

QURIS-AI BEST PARTNERSHIP ALLIANCE AWARD

The Best Partnership Alliance Award recognises the importance of pharmaceutical and/or biotech companies working together to develop new medicines from the earliest stages.

This category seeks to reward innovative partnerships between companies in which they share the risks and rewards inherent in exploring novel therapeutic strategies and developing new drugs.

The judges will be focusing on deals that require strong strategic input from both partners, involving R&D, business development or joint marketing/promotion. They are looking for those deals that are the most mutually beneficial, have the most strategic potential, and are innovative in their structure. Partnerships must have been announced, or have achieved a significant milestone, between 1 July 2023 - 30 June 2024, and entrants should be able to show some benefits arising from the deal.

Please note, this Award does not cover the licensing of a particular drug, project or group of closely related drugs/projects from one company to another for further development and/or marketing (see Criteria for Licensing Deal of the Year).

SPONSORED BY



To enter this category, please answer the following:

- ◇ Please give the name of the company or organizations involved.
- ◇ Please outline the structure of the partnership, detailing the parties involved, what it covers and the responsibilities on both sides.
- ◇ Does its structure represent an innovative research or business model, and if so how?
- ◇ Please summarize the strategic and/or research potential of the deal and, if applicable, any milestones reached.
- ◇ How does the collaboration hope to meet any unmet medical need?
- ◇ Please explain how the deal is mutually beneficial to both parties. How does it demonstrate that either party was the "partner of choice"?

BUSINESS DEVELOPMENT TEAM OF THE YEAR

Scrip's Business Development Team of the Year Award will honor the achievements of business development teams whether they are from a pharma or biotech company or a cross-company team responsible for a specific deal or collaborative project.

This Award will go to a team that is truly much more than the sum of its parts. The Judges will be looking for strong performance across a number of criteria, such as achievement of short- and long-term goals, and good communication of a shared vision.

To enter this category, please answer the following:

- ◇ Please give details of the company and companies, the particular team being entered and its core function.
- ◇ Please describe the team's goals and vision, and how these are communicated.
- ◇ What was the greatest achievement of the team during the year between 1 July 2023 - 30 June 2024?
- ◇ Please describe how all parts of the team were fully aligned to achieve this, including how supporting functions, such as HR, finance and IT, were integrated into the team.
- ◇ Rate the team, giving justification, according to the following criteria:
 - Achieving short-term and long-term goals
 - Managing resources
 - Providing a platform for professional development and teamwork
 - How does the team embody a management model that others should follow?

EXECUTIVE OF THE YEAR

Scrip's Executive of the Year Award is designed to acknowledge excellence in the leadership of large and small pharmaceutical and biotechnology companies.

This year's winner will be the executive who has exhibited exemplary leadership throughout the year from 1 July 2023 - 30 June 2024. This could range from leading an emerging company to an established place within the industry, to turning around the fortunes of a failing company or unit, or leading a firm successfully through the turbulence of a merger or acquisition. Also important to the judges will be the executive's career achievements, influence within the industry and leadership qualities.

To be eligible for this year's Award, entrants must hold a C-suite executive position. Candidates must be employed by the company at the time of nomination.

To enter this category, please answer the following:

- ◇ Please give the name, company and position of the entrant, and the date of taking up this post.
- ◇ What have been the entrant's greatest achievements during the qualifying year?
- ◇ What has been the direct consequence of these on company performance?
- ◇ How have these achievements strengthened the candidate's influence within the industry? Please give examples.
- ◇ What are the entrant's greatest strengths as a leader? Please show how these have had a bearing on their achievements this year.
- ◇ What specific previous accomplishments did the entrant have that made them perfectly fitted to achieving this success? For example, previous scientific or management experience.

BEST CONTRACT RESEARCH ORGANIZATION FULL SERVICE PROVIDERS

The Awards for the Best Contract Research Organization acknowledge the critical role that CROs play in drug development.

Clinical outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies' experience in handling all aspects of clinical trials. The Awards for CROs are split into two sister categories to separate the larger full-service providers from those smaller CROs that provide specialist services to their clients.

This Award is for the companies who provide the full range of clinical research services and they will be judged on the quality of these services and relationships the firms have built with their clients. It will pay particular attention to the innovative patient recruitment strategies the CRO has brought to the deal. To qualify, candidates must draw on their achievements in the year between 1 July 2023 - 30 June 2024.

SPONSORED BY



To enter this category, please answer the following:

- ◇ What particular capabilities and strengths does the CRO offer?
- ◇ How has this firm delivered results that exceed sponsor expectations?
- ◇ How has the CRO advanced drug development through use of real-world data and real-world evidence?
- ◇ What innovations in patient engagement and recruitment has the CRO brought to its partner?
- ◇ How has it improved its performance in promoting diversity and inclusion of underrepresented populations within a clinical trial or drug development program?
- ◇ How has it improved its performance in leveraging artificial intelligence to improve a clinical trial process, or to support the successful operations of a clinical trial?

BEST CONTRACT RESEARCH ORGANIZATION SPECIALIST PROVIDERS

The Awards for the Best Contract Research Organization acknowledge the critical role that CROs play in drug development.

Clinical outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies' experience in handling all aspects of clinical trials. The Awards for CROs are split into two categories to separate the larger full-service providers from those smaller CROs that provide specialist services to their clients.

This Award is for those companies who provide niche services to their clients will be judged on the quality of these services and relationships they have built with their clients. To qualify, candidates must draw on their achievements in the year between 1 July 2023 - 30 June 2024.

To enter this category, please answer the following:

- ◇ What particular capabilities and strengths does the CRO offer?
- ◇ How has this firm delivered results that exceed sponsor expectations?
- ◇ What product or suite of products does the CRO have that help study teams better manage and oversee clinical trial activities?
- ◇ How has it improved its performance, for example, in its quality of data, timelines and transparency, or use of artificial intelligence and real-world evidence?
- ◇ What steps is the company taking towards helping sponsors improve diversity and inclusion?

BIOTECH COMPANY OF THE YEAR

The biotech industry's entrepreneurial spirit and cutting-edge science have transformed the research and development of medicines in the past few decades.

This Award honors outstanding achievement by biotech companies over the qualifying 12 months.

The winner of the Biotech Company of the Year Award will be the biotech firm that has achieved the most in the 12 months between 1 July 2023 - 30 June 2024. For example, this could be moving the business from an early stage to a more mature company, signing a transformative deal, taking its first or a major new product towards the market, or raising significant new funds.

To enter this category, please answer the following:

- ◇ Name of entering company
- ◇ What has been the company's most significant achievement during the year?
- ◇ Give details of what the firm has accomplished over the year in terms of:
 - Bringing new products closer to their first markets
 - Raising funds
 - Signing significant licensing or partnership deals
 - Showing strong management not afraid of making hard decisions
 - Using proprietary science or technologies to address an unmet medical need
 - Successfully transforming the business from an early stage to a more mature company

View our Biotech Company of the Year example entry form [here](#)

www.citeline.com/awards/ScripAwards

ENTRY AND GENERAL ENQUIRIES:

Jo Kirkpatrick, Senior Events Manager

Tel: +44 (0) 7917 555 986 • Email: jo.kirkpatrick@citeline.com

BEST NEW DRUG AWARD

The Best New Drug Award recognises excellence in pharmaceutical development. Launching innovative new products is the most important function of the industry, and a successful new drug launch marks the culmination of years of risky and expensive R&D.

In this category, the judges will be looking for the small-molecule or biological product that was approved in its first market worldwide during the qualifying period that represents the best therapeutic advance in its area.

All recently launched new active substances, including small molecules, biologicals or vaccines, are eligible to enter so long as they were first licensed in any market between 1 July 2023 - 30 June 2024. Generic and biosimilar products are not eligible for this Award.

Entrants must have played a role in the development of the nominated product, and all parties to joint ventures should be disclosed in the application.

View our Best New Drug example entry form [here](#)

www.citeline.com/awards/ScripAwards

To enter this category, please answer the following:

- ◇ Please give the trade and generic name of the entrant, the therapeutic indication for which it is being considered, and the company or companies involved in its development (if more than one company, please detail the relationship between the parties)
- ◇ What was the date and market of the candidate's first approval and launch?
- ◇ Please explain the mechanism of action of the candidate. How does this represent a step forward in treatment in this therapeutic area?
- ◇ Please outline the evidence for the product's clinical activity. How does its activity translate into a meaningful therapeutic benefit for patients, and how is this benefit over and above that provided by other treatments in this area?
- ◇ How does the entrant address an unmet medical need?
- ◇ What is the potential market size of the candidate?

BEST ONCOLOGY R&D ADVANCE

This Scrip Award seeks to recognise early clinical advances in oncology made by small biopharma companies.

The great strides seen in cancer therapies in recent years often had their genesis in the labs of specialist firms. We are looking to reward companies that are exploiting new knowledge in cancer cell biology and the tumor microenvironment to forge new paths to tackle the disease, for instance by developing novel therapeutic strategies in immuno-oncology, gene and cell therapies and new targeted agents.

This category is aimed at clinical-stage oncology firms pioneering new approaches in the treatment of cancer that have shown proof of concept in early (Phase I or II) clinical trials and have candidates moving forward in the development pathway.

Entries should be from clinical-stage firms with novel products that have shown proof-of-concept in some way between 1 July 2023 - 30 June 2024, such as a clinical study that has been reported by the firm, presented for peer review at a medical meeting or published in a scientific journal.

Entrants must have played a role in the clinical study and all joint parties must be disclosed in the application.

*Please note, Preclinical advances may work best in **MSD's Innovation Award** and later-stage studies and those by big pharma firms may be best suited to the **Clinical Advance of the Year** category*

To enter this category, please answer the following:

- ◇ Please give the name of the originator company and the product being entered
- ◇ Please detail the proof-of-concept study, giving its name (protocol ID, trial identifier), phase, disease type and patient segment studied
- ◇ Please summarize the major findings of the study, including all endpoints
- ◇ Please explain how the product is shown to exert a therapeutic effect in this setting and where its novelty lies
- ◇ How do these findings represent a potential advance in treating cancer, and what are their implications for other cancer types?
- ◇ How is this advance expected to disrupt and/or fit into the current therapeutic strategy/ies for its intended indication/s?

ENTRY AND GENERAL ENQUIRIES:

Jo Kirkpatrick, Senior Events Manager

Tel: +44 (0) 7917 555 986 • Email: jo.kirkpatrick@citeline.com

PHARMA COMPANY OF THE YEAR

SPONSORED BY



The Pharma Company of the Year Award honors outstanding achievements by pharmaceutical companies over the qualifying 12 months between 1 July 2023 - 30 June 2024.

This special Award is chosen by Scrip's senior editorial team, based on a variety of key metrics:

- ◇ Financial performance in 2023 compared with the previous year
- ◇ Strategic advances, looking at its most significant achievements over the year
- ◇ Progress in the expanding into new and emerging markets
- ◇ New product launches, including line-extensions and formulations
- ◇ Advances in the drug pipeline, including major clinical trial reports



www.citeline.com/awards/ScripAwards

SCRIP'S LIFETIME ACHIEVEMENT AWARD

SPONSORED BY



The winner of this Award will be an exceptional individual with a consistent history of service, above and beyond the call of duty, throughout their career.

This prestigious international Award will go to someone who has had a distinguished career in the biotech or pharmaceutical arena, primarily within industry.

For this special Award, candidates must be nominated by a third party. The nomination should outline in no more than 750 words what the nominee has accomplished during his/her career and say why they are worthy of this Award.

Nominees may be retired or semi-retired but will still be active in the industry in some capacity.

All nominations must include:

- ◇ Name of the nominee
- ◇ Job title of the nominee (if applicable)
- ◇ Company name (if applicable)
- ◇ Your contact details
- ◇ Contact details of the nominee
- ◇ A précis of up to 750 words of why you think your nominee is worthy of receiving the Lifetime Achievement Award.



ENTRY AND GENERAL ENQUIRIES:

Jo Kirkpatrick, Senior Events Manager

Tel: +44 (0) 7917 555 986 • Email: jo.kirkpatrick@citeline.com

HOW DO THE JUDGES SELECT THE AWARD WINNERS?

The Scrip Awards prides itself on its Judging Panel, comprised of independent, senior industry experts from around the world, each chosen for their knowledge, objectivity and credibility.

The judges separately consider entries from those categories that are relevant to their particular areas of specialist knowledge, expertise and experience, ensuring a considered response to every individual submission. Each category is reviewed by at least three judges.

The judges mark each entry against the published category criteria, and the scores are marked out of ten for each answer. These are then collated by the Scrip Awards team to determine which entries are included in the shortlist, and the ultimate winner.

The chair of the Judging Panel reserves the right to cast any deciding vote, should the need arise. The judges' decision is final and neither the organizers nor the Judging Panel will enter into any correspondence about the results. Judging will take place throughout the summer, and the shortlist will be announced in September.

Details of the winners are strictly embargoed until the night but further details of all of the shortlisted entries will be published on the Scrip Awards website in the weeks leading up to the ceremony on Wednesday, 4 December, 2024 at Raffles London at The OWO.

USEFUL TIPS FOR A WINNING ENTRY:

- ◇ Read the entry details and judging criteria carefully for each category before starting your submission.
- ◇ Write your entry specifically for the category in question, check the nomination is in the correct category and would not stand a better chance of winning in a different category.
- ◇ Do not exceed the word limit. Entries should be 1,500 words, entry summaries 250 words, and there should be no supporting material.
- ◇ Ensure the activities included were undertaken between the date parameters, 1 July 2023 - 30 June 2024.
- ◇ Ensure each entry meets the specific criteria for its category.
- ◇ Ensure you have answered each question under a separate heading in your submission.
- ◇ Plan ahead to ensure it's submitted in plenty of time so that, should it be incomplete, there will still be time to correct and re-submit it before the closing date of 12 July 2024.

THE RULES :

- ◇ All entries must be written in English.
- ◇ All entries must be accompanied by a 250-word synopsis of the entry which may be used in Awards publicity material (this is in addition to the entry).
- ◇ All entries must be submitted via our online entry system.
- ◇ All entries must be based on activities undertaken from activities undertaken since 1 July 2023 - 30 June 2024.
- ◇ Answer each question under a separate heading, as specified in the category criteria.
- ◇ Do not provide any supporting documentation – all information should be included within your entry.
- ◇ Plan ahead to ensure it arrives in plenty of time so that, should it be incomplete, there will still be time to correct and resubmit it before the closing date.
- ◇ All entries will be treated as confidential, but Scrip reserves the right to publish positive extracts from the winning entries' 250-word synopses.
- ◇ All companies shortlisted as finalists will be notified directly by the Scrip Awards team in September.
- ◇ The Judging Panel reserves the right to move an entry into a different category if they feel it is better suited in this category.

CONFIDENTIALITY

- ◇ Citeline, organizer of the Scrip Awards, recognises and respects the sensitive nature of the information submitted in the entries. We ensure that this recognition is shared by our Judging Panel, and, therefore, require each judge to sign a confidentiality agreement before they are appointed. Entries are not disclosed or discussed outside the judging process.
- ◇ The Judging Panel for each Award is selected to avoid any conflict of interest. Once an entry is shortlisted, extracts from the entry summary only will be sourced for inclusion in the Awards ceremony and any subsequent editorial coverage.
- ◇ Please ensure your entry summary contains no confidential or sensitive information.

Entering more than one category:

- ◇ Companies may enter more than one category, provided that each entry has been specifically written to address the relevant criteria and is accompanied by a separate 250-word synopsis.

FAQS

Q. How do I enter?

A. It's very simple. Ensure you have read the entry guidelines and category criteria. Decide on which category (or categories) you wish to enter, and create your online account via www.citeline.com/awards/ScripAwards

Once you are ready click 'Enter Now', follow the on screen instructions and submit your entry by clicking 'Enter'.

Q. How much does it cost to enter?

A. Entries for the Scrip Awards are free of charge.

Q. When is the entry deadline?

A. Entries are being accepted until 12 July, 2024.

Q. I am not sure which category our entry would fit into?

A. If you are not sure which category your entry fits into, please contact Jo Kirkpatrick at jo.kirkpatrick@citeline.com for further assistance.

Q. Can I enter the same submission into more than one category?

A. We encourage entries in more than one category per individual or company, where appropriate; please ensure to review the category criteria and tailor your entry accordingly.

Q. I am a sponsor of the Awards, am I still able to enter?

A. Yes you can enter the Awards. And we would encourage this, however you are unable to enter the category you are sponsoring. Don't worry, there are plenty of other categories.

Q. How will I know whether my submission has been received?

A. All submissions will be acknowledged by an automated email once you have submitted your entry. Our Awards team will also get in touch with you again shortly before the entry deadline. If you have any concerns, please contact Jo Kirkpatrick at jo.kirkpatrick@citeline.com

Q. How will I know if my submission has been successful?

A. Following the judging all companies and individuals will be notified by email. Finalists will be announced on www.citeline.com/awards/ScripAwards. If you are successful, you will also receive an email from us on what happens next.

Q. What do I get if I win?

A. The Scrip Awards are highly regarded within the industry and winning an Award marks you out as a leader in your field. In addition to your trophy (if in attendance at the ceremony) and a certificate of recognition you will receive a winner's pack with additional details on publicising your success.

Q. How can I ensure I'm at the Awards ceremony for networking?

A. It's essential to book your place at the event. Please contact Casey Burwell, Global Sales Manager, email: casey.burwell@citeline.com

Q. Are there other ways I can get involved in the Awards?

A. Yes, there are a variety of sponsorship opportunities available. Please contact Casey Burwell, Global Sales Manager, email: casey.burwell@citeline.com

Q. Can I see an example entry form?

A. Yes, we have created 3 example entries forms to help you. These available to view at the bottom of the following category pages; Licensing Deal of the Year, Biotech Company of the Year and Best New Drug Award.

SCRIP AWARDS — 2024 —

WEDNESDAY 4 DECEMBER 2024 · RAFFLES LONDON AT THE OWO



ENTRY AND GENERAL ENQUIRIES:

Jo Kirkpatrick

Senior Events Manager
Email: jo.kirkpatrick@citeline.com

SPONSORSHIP ENQUIRIES:

Casey Burwell

Global Sales Manager
Email: casey.burwell@citeline.com